Prime Medicine vs Entrada Therapeutics
PRME and TRDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRME and TRDA compare
Prime Medicine is the larger company, worth 3.7 times as much as Entrada Therapeutics ($780M against $212M).
Entrada Therapeutics scores higher on the StockData Score (6 against 5 for Prime Medicine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRME | TRDA |
|---|---|---|
| Size and price | ||
| Market cap | $780M | $212M |
| Share price | $4.30 | $5.44 |
| Change, 1 year | 22.0% | −25.1% |
| Change, 5 years | −79.6% | −83.4% |
| Beta (5Y) | 0.43 | 0.97 |
| Employees | 146 | 152 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 53.3× |
| P/B | 19.6× | 1.1× (better) |
| FCF yield | −20.1% (better) | −64.4% |
| Growth | ||
| Revenue growth (TTM) | – | −93.5% |
| Revenue growth, 5Y average | −2.3% | – |
| Profitability | ||
| Operating margin | – | −4304% |
| Net margin | – | −4058% |
| FCF margin | – | −3428% |
| Return on equity | −373% | −59.9% (better) |
| Return on invested capital | – | −1406% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.05 | 7.85 (better) |
| Altman Z-score | −5.56 | −1.53 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 58.8% | 75.6% |
| Held by insiders | 18.6% | 14.8% |
| Insider net buying, 12 months | – | −$11.5M |
| Short interest, % of float | 19.7% | 8.5% |
Go deeper
- PRME stock overview
- PRME income statement
- PRME valuation and score
- TRDA stock overview
- TRDA income statement
- TRDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.